Role of peroxisome proliferator-activated receptor {delta}/{beta} in hepatic metabolic regulation. - Wikidata - wikimedia - TriplyDB

Role of peroxisome proliferator-activated receptor {delta}/{beta} in hepatic metabolic regulation.

Role of peroxisome proliferator-activated receptor {delta}/{beta} in hepatic metabolic regulation.

http://www.wikidata.org/entity/Q34488953

about

The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention Transcriptional repression of mitochondrial function in aging: a novel role for the silencing mediator of retinoid and thyroid hormone receptors co-repressor Energy metabolism in the liver PPARγ as a therapeutic target to rescue mitochondrial function in neurological disease PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD.Retinoic acid-related orphan receptor γ (RORγ): a novel participant in the diurnal regulation of hepatic gluconeogenesis and insulin sensitivity PPARδ activation attenuates hepatic steatosis in Ldlr-/- mice by enhanced fat oxidation, reduced lipogenesis, and improved insulin sensitivity Lipid metabolites as metabolic messengers in inter-organ communication.Molecular pathways in non-alcoholic fatty liver disease.Increased fat mass is associated with increased bone size but reduced volumetric density in pre pubertal children A diurnal serum lipid integrates hepatic lipogenesis and peripheral fatty acid use.Transcriptomic analysis of hepatic responses to testosterone deficiency in miniature pigs fed a high-cholesterol diet.Integrative and systemic approaches for evaluating PPARβ/δ (PPARD) function.Alteration of hepatic nuclear receptor-mediated signaling pathways in hepatitis C virus patients with and without a history of alcohol drinking.Dissecting the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in colon, breast, and lung carcinogenesis.Muscle ring finger-3 protects against diabetic cardiomyopathy induced by a high fat diet.MuRF2 regulates PPARγ1 activity to protect against diabetic cardiomyopathy and enhance weight gain induced by a high fat diet.Development of PPAR-agonist GW0742 as antidiabetic drug: study in animals.PPARs in Liver Diseases and Cancer: Epigenetic Regulation by MicroRNAs.Immunomodulatory glycan LNFPIII alleviates hepatosteatosis and insulin resistance through direct and indirect control of metabolic pathways Misregulation of PPAR Functioning and Its Pathogenic Consequences Associated with Nonalcoholic Fatty Liver Disease in Human Obesity.Direct control of hepatic glucose production by interleukin-13 in mice.Nuclear control of the inflammatory response in mammals by peroxisome proliferator-activated receptors Combined pharmacological activation of AMPK and PPARδ potentiates the effects of exercise in trained mice.PPARs and Mitochondrial Metabolism: From NAFLD to HCC.Genetic dissection of retinoid esterification and accumulation in the liver and adipose tissue.PPARδ activation induces hepatic long-chain acyl-CoA synthetase 4 expression in vivo and in vitro.PPARγ Antagonist Gleevec Improves Insulin Sensitivity and Promotes the Browning of White Adipose Tissue.Overfeeding Dairy Cattle During Late-Pregnancy Alters Hepatic PPARα-Regulated Pathways Including Hepatokines: Impact on Metabolism and Peripheral Insulin Sensitivity.Pharmacological agents for NASH.Non-alcoholic fatty liver disease: the role of nuclear receptors and circadian rhythmicity.Evolving therapies for non-alcoholic steatohepatitis.PPARs and ERRs: molecular mediators of mitochondrial metabolism.Phytoceramide and sphingoid bases derived from brewer's yeast Saccharomyces pastorianus activate peroxisome proliferator-activated receptors.PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ.Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans.A Combination of Leucine, Metformin, and Sildenafil Treats Nonalcoholic Fatty Liver Disease and Steatohepatitis in Mice.Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome.Distinct but complementary contributions of PPAR isotypes to energy homeostasis.

P2860

Q24601222-D08ECFE0-7378-487C-A59A-0329008918A4 Q26992046-3378E4EE-E6A0-462E-A3C5-E5AAFF133750 Q26996783-E3780017-9007-45C6-9D51-48AA478CC980 Q28069549-964F22E0-4F1E-41C6-8121-F94F4AF004C6 Q30241952-0B7B2523-5BCD-4AC5-B659-CDD0729EF0D1 Q33617767-B77D1EE5-2248-401B-9192-F8FFC67AB71B Q33825128-119273BB-DA0D-41C0-9596-D7E866D83D16 Q33831533-0F4CF818-CCD4-4332-B22B-CB83285D1D6C Q33890230-A5AA59F0-590C-4A7C-A66E-1F00F160E211 Q33907379-9D812757-BDE0-4CC1-8559-9D7B2F9AD37A Q34078111-A81E790A-5B36-40C6-B003-F7DF4798F320 Q35084113-422E8F6C-F540-48E2-BB9F-919F80D2E46E Q35569436-7FF24C87-D16D-45C1-A9DA-680D9E39320E Q35592839-E0350730-349C-4B45-B40B-37651CF846D2 Q35613331-D82C1074-96D1-494B-9D28-DB8E55B18804 Q35716907-9C19EC0B-D428-43AA-9DDE-C97B017329B0 Q35920226-33A0B801-E7C9-4531-BAED-1D419447A134 Q36176775-01D74249-78C0-4D75-849A-A61C323F0F1C Q36253614-92CBE434-0ADA-4236-AF4D-63D318137EE4 Q36385717-F64DB989-FB2E-46DC-8ED8-F820A1DFAA64 Q36478196-AFA18CA3-5569-4354-8E83-DCFF50E792C5 Q36497258-9E5D5778-D954-42FB-B7CA-5F3CE96D4C7A Q36733873-8D0BE635-0409-4ACE-AC33-12701544D018 Q36773746-2250CFD3-1482-40A5-988B-82187AC5C101 Q37575571-1F545224-582F-4CF0-965C-E3B179FA6CCF Q37590272-FEA0AD46-D551-488E-B7A8-D8D212DAAE5B Q37625952-9B04DCB3-2FBF-4CA1-9F33-5DB14E17EA2C Q37649336-E241A3DB-8D00-4E46-A162-9BBBC75082EA Q37694629-032BCDD2-E3B9-4724-AC8B-4142D238E3A8 Q38152646-A071E021-02D7-49E8-8980-FDCB0FD3DC4C Q38197690-2512570C-3DBB-4031-A8A6-FCABC1801812 Q38207111-ABFED11B-B6D6-44D3-845E-AAFDE2772174 Q38285171-3E8FFFA4-71BC-4890-AF75-A3AB895CB7F3 Q38520014-624044C9-F6D7-4C71-98DB-E736A04AD4D4 Q38674739-FF9C0017-B298-4851-B4F7-B6548C534E2A Q38698442-5106A7AA-BB19-4CCB-9F07-21242BF75F8E Q38752520-E0E3EDB6-1C30-4612-98CF-2F77A4B66C64 Q39044686-A81E0128-8FDD-4CD6-BCE0-AFFB4966EC77 Q39090639-BE4438BE-CDD3-4ACD-BC2B-A92E171FC27B Q39214885-BC7E4FFF-8F46-4F59-9A84-29EC737AB6B2

P2860

Role of peroxisome proliferator-activated receptor {delta}/{beta} in hepatic metabolic regulation.

http://www.wikidata.org/entity/Q34488953

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Role of peroxisome proliferato ...... hepatic metabolic regulation.

@ast

Role of peroxisome proliferato ...... hepatic metabolic regulation.

@en

Role of peroxisome proliferato ...... hepatic metabolic regulation.

@nl

type

label

Role of peroxisome proliferato ...... hepatic metabolic regulation.

@ast

Role of peroxisome proliferato ...... hepatic metabolic regulation.

@en

Role of peroxisome proliferato ...... hepatic metabolic regulation.

@nl

prefLabel

Role of peroxisome proliferato ...... hepatic metabolic regulation.

@ast

Role of peroxisome proliferato ...... hepatic metabolic regulation.

@en

Role of peroxisome proliferato ...... hepatic metabolic regulation.

@nl

P1433

Q34488953-92E10C44-5DCA-448F-8B7A-099B8B04C36A

P1476

Q34488953-EAC16ED4-63B4-4CE0-9762-58C76887CEDF

P2093

Q34488953-2A39E6C0-B408-4C62-8E61-F4DE94F30F8E

Q34488953-3EC30D33-A4B6-4DC4-AC94-10DF4F0B9D55

Q34488953-5EEB6290-3430-43B8-A8C9-A197A53EE017

Q34488953-609E69EB-16AD-4CAB-9730-1378C6CFEA35

Q34488953-76917788-1595-4DF4-98B1-E566E5211E51

Q34488953-839D6758-99F6-4499-9F31-57E6ACC01546

Q34488953-BE73B35B-CE1A-404F-8429-A842C7AEEBB1

Q34488953-C8783161-6C44-4C03-A2FE-EB24C64961F0

Q34488953-E2A3527D-4EBC-49BF-8F60-9EB8FBE5DD55

Q34488953-FF8B1D9A-FE84-4511-A56E-CC88E361D99E

P2860

Q34488953-02B055EC-34EB-4EA6-85A1-F7766E4E975D

Q34488953-052AC395-9D98-46B2-9864-0664B11077B2

Q34488953-09FC681E-E05A-48F2-8224-BCDE3BB99C11

Q34488953-165FDAA7-D45F-4A5E-BC7F-E02B03C5A448

Q34488953-1B0F0C18-5D12-459C-93EC-4729B110BCF7

Q34488953-2519DE6B-4FA5-41F5-ABB2-DB0AB7810A8B

Q34488953-26EBC8A4-2981-4370-B414-FBDF93624999

Q34488953-29C4AEBE-FBF3-46A2-9601-95536E5A3C17

Q34488953-2B973913-B0DC-40FE-A254-8FF66E6FB254

Q34488953-32B21C58-CAC4-441D-AFB4-B382E5CB41F6

P304

Q34488953-F711FD95-00F0-455F-B91D-214B271E92CF

P31

Q34488953-A2DE785C-EC69-4ECB-9663-0AC9CC08163C

P356

Q34488953-831F9129-0B13-4947-9C20-C24DF9AB797D

P407

Q34488953-49FE9F9D-26AD-4FF8-A955-EE13B8B80113

P433

Q34488953-3413C5F0-9E1F-4F99-97CD-BB322AABA9C6

P478

Q34488953-CD6CD4F0-5A0A-401D-9E31-C74196FB32D8

P50

Q34488953-DB5741BD-ED3D-4C67-B3B4-C13F45DFD62D

P577

Q34488953-5D89577D-C58C-43F6-966C-006BE8CE737C

P698

Q34488953-C0E36A21-5EF5-47B3-A4B9-F516748D5A2F

P932

Q34488953-AC1D71F0-0DA1-44B8-A4F9-F753C1FCB3BF

P356

JBC.M110.138115

P1433

Journal of Biological Chemistry

P1476

Role of peroxisome proliferato ...... n hepatic metabolic regulation

@en

P2093

Ben Hatano

http://www.w3.org/2001/XMLSchema#string

Cem Gorgun

http://www.w3.org/2001/XMLSchema#string

Chen-Chung Yen

http://www.w3.org/2001/XMLSchema#string

Chih-Hao Lee

http://www.w3.org/2001/XMLSchema#string

James A Balschi

http://www.w3.org/2001/XMLSchema#string

James M Ntambi

http://www.w3.org/2001/XMLSchema#string

Kihwa Kang

http://www.w3.org/2001/XMLSchema#string

Matthew R Gangl

http://www.w3.org/2001/XMLSchema#string

Minghui Zhao

http://www.w3.org/2001/XMLSchema#string

Sihao Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration

Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase

PPARdelta regulates glucose metabolism and insulin sensitivity

A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport

Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism

Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators

AMPK and PPARdelta agonists are exercise mimetics

Regulation of muscle fiber type and running endurance by PPARdelta

Inflammation and metabolic disorders

Alternative activation of macrophages

P304

1237-1247

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M110.138115

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

286

http://www.w3.org/2001/XMLSchema#string

P50

Shannon M Reilly

P577

2010-11-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21059653

http://www.w3.org/2001/XMLSchema#string

P932

3020731

http://www.w3.org/2001/XMLSchema#string